Is TRT healthier than living with low testosterone? What the data shows

What's this video probably claiming?

Marc Lobliner, a well-known fitness industry figure with a long history in supplement marketing and bodybuilding content, is almost certainly arguing that treating clinically low testosterone with TRT produces better health outcomes than leaving hypogonadism untreated. That framing, 'TRT is healthier than low T,' is a popular narrative in the testosterone optimization space right now. Based on the caption's confident phrasing, 'the answer is a clear yes,' the video likely cites cardiovascular benefits, improved metabolic markers, mood, libido, and possibly longevity data. He may reference the TRAVERSE trial or observational studies linking low testosterone to increased all-cause mortality. The argument is not without merit, but 'a clear yes' is doing a lot of heavy lifting here. The nuance around who benefits, at what baseline, and for how long gets lost fast in short-form content.

What does the science actually show?

The evidence is genuinely more supportive of TRT than it was a decade ago, but 'clear yes' is still an overstatement. The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) was a landmark study of over 5,200 men with hypogonadism and existing cardiovascular risk. It found TRT was non-inferior to placebo for major adverse cardiac events over about 33 months, which settled a long-running safety scare from a badly designed 2010 study. That is good news. However, TRAVERSE also found increased rates of pulmonary embolism and atrial fibrillation in the TRT group. Separately, a 2016 meta-analysis by Corona et al. in the Journal of Sexual Medicine found TRT improved body composition, insulin sensitivity, and sexual function in men with confirmed hypogonadism, total testosterone below roughly 300 ng/dL. Benefits outside that population are much less established. The word 'healthier' implies universal benefit. The data does not support that.

Where does the social media noise diverge from clinical reality?

The biggest distortion in TRT content is the conflation of clinical hypogonadism with 'suboptimal' testosterone levels that fall within normal range. Clinical hypogonadism is defined by most endocrinology guidelines, including the Endocrine Society's 2018 guidelines, as a total testosterone below 300 ng/dL with corresponding symptoms. A significant portion of men pursuing TRT online have levels between 300 and 500 ng/dL and are essentially self-diagnosing based on symptoms like fatigue and low libido that have multiple causes. Videos like this one often ignore that distinction entirely. There is also a meaningful gap between what short-term trials measure and what decades of exogenous testosterone do to endogenous production, fertility, and hematocrit. The polycythemia risk is real: TRT raises hematocrit, and values above 54 percent are associated with increased thrombotic risk per American Urological Association guidelines. That gets mentioned rarely in 7,000-view TikToks.

What should you actually know?

If you have confirmed hypogonadism, meaning a documented low total testosterone on two morning fasting blood draws plus genuine symptoms, the benefit-to-risk calculation has shifted meaningfully in TRT's favor since TRAVERSE. That is worth knowing. But 'TRT is healthier than low T' as a blanket statement skips several steps. First, get a proper diagnosis. Second, understand that TRT suppresses natural testosterone production, often permanently, requiring lifetime treatment. Third, know your hematocrit and PSA at baseline and monitor them. Fourth, recognize that Lobliner has commercial interests in the supplement and fitness space, which does not make him wrong, but it means you should weigh his framing accordingly. The Endocrine Society, European Association of Urology, and AUA all recommend TRT for confirmed hypogonadism. None endorse it for age-related 'optimization' in men with normal levels.